by TractManager | Jun 27, 2019 | Emerging Technology Report
Zulresso (brexanolone) is a sterile solution of allopregnanolone for intravenous infusion in development for the treatment of postpartum depression (PPD). Allopregnanolone is a positive allosteric modulator of the neurotransmitter gamma-aminobutyric acid (GABAA)...
by TractManager | Jun 27, 2019 | Emerging Technology Report
Zulresso (brexanolone) is a sterile solution of allopregnanolone for intravenous infusion in development for the treatment of postpartum depression (PPD). Allopregnanolone is a positive allosteric modulator of the neurotransmitter gamma-aminobutyric acid (GABAA)...
by TractManager | Jun 26, 2019 | Emerging Technology Report
Celiprolol is an oral beta-1 adrenoceptor antagonist with partial beta-2 agonist activity proposed for the prevention of complications of vascular Ehlers-Danlos syndrome (EDS). Celiprolol has antihypertensive and antianginal properties, in addition to influencing...
by TractManager | Jun 26, 2019 | Emerging Technology Report
Celiprolol is an oral beta-1 adrenoceptor antagonist with partial beta-2 agonist activity proposed for the prevention of complications of vascular Ehlers-Danlos syndrome (EDS). Celiprolol has antihypertensive and antianginal properties, in addition to influencing...
by TractManager | Jun 21, 2019 | Clinical Utility Evaluation
This report evaluates the clinical utility of genetic testing in patients with or suspected of congenital and/or prelingual nonsyndromic hearing loss.If you have a Hayes login, click here to view the full report on the Knowledge Center.
Recent Comments